How does NEREUS™ work?
NEREUS™ blocks NK-1 receptors in the brain, interrupting the vomiting pathway triggered by motion sickness.
Yanuki
ARTICLE DETAIL
NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment | Former South Carolina QB Stephen Garcia Diagnosed with Stage 4 Colorectal Cancer | Norovirus Outbreak on Caribbean Princess Cruise Ship | Jordan Peterson's Health Concerns and Akathisia Awareness | Fiji Grapples with Soaring HIV Cases: An Alarming Outbreak | Newborns Bleeding to Death in US: The Vitamin K Debate | Dave Coulier Reveals 45-Pound Weight Loss from Cancer Treatment | Biohacking Vaginal Health: Trends and Insights | Hantavirus Outbreak Linked to Cruise Ship and KLM Flight: What You Need to Know | NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment | Former South Carolina QB Stephen Garcia Diagnosed with Stage 4 Colorectal Cancer | Norovirus Outbreak on Caribbean Princess Cruise Ship | Jordan Peterson's Health Concerns and Akathisia Awareness | Fiji Grapples with Soaring HIV Cases: An Alarming Outbreak | Newborns Bleeding to Death in US: The Vitamin K Debate | Dave Coulier Reveals 45-Pound Weight Loss from Cancer Treatment | Biohacking Vaginal Health: Trends and Insights | Hantavirus Outbreak Linked to Cruise Ship and KLM Flight: What You Need to Know
Health / Pharmaceuticals
NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment
After more than four decades, a new prescription medicine has emerged to combat motion sickness. Vanda Pharmaceuticals has announced the U.S. commercial availability of NEREUS™ (tradipitant), offering a modern, targeted approach to prevent...
Key Insights
- NEREUS™ (tradipitant) is the first new prescription medicine approved for motion sickness in over 40 years.
- It's estimated that 25 to 30 percent of American adults (65 to 78 million people) experience motion sickness during travel.
- NEREUS™ is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors, blocking the vomiting center of the brain.
- A direct-to-consumer platform at nereus.us&ref=yanuki.com offers NEREUS™ at a cash-pay price of $85 per dose, a discount from the standard list price of $255.
In-Depth Analysis
Motion sickness occurs when the brain receives conflicting signals from the eyes, inner ear, and body during motion. This sensory mismatch triggers the release of substance P, activating NK-1 receptors in the central nervous system, leading to nausea and vomiting. NEREUS™ works by blocking these receptors, interrupting this pathway.
The FDA approved NEREUS™ on December 30, 2025, based on two Phase 3 clinical trials (Motion Syros and Motion Serifos) conducted under real-world sea travel conditions. These studies demonstrated that NEREUS™ significantly prevented vomiting compared to a placebo.
However, it's important to note that NEREUS™ may impair abilities required for driving or operating heavy machinery and is not recommended for patients with liver or severe kidney problems. The most common side effects include drowsiness, headache, and fatigue. These factors should be carefully considered when choosing a motion sickness treatment.
Vanda Pharmaceuticals' commercial strategy involves a significant price spread between its direct-to-consumer portal and traditional pharmacies, incentivizing patients to bypass insurance and purchase directly from nereus.us&ref=yanuki.com.
FAQ
What are the common side effects of NEREUS™?
The most common side effects include drowsiness, headache, and fatigue.
Where can I purchase NEREUS™?
NEREUS™ is available by prescription through retail pharmacies nationwide and directly through nereus.us&ref=yanuki.com.
Takeaways
- NEREUS™ (tradipitant) is a novel treatment for motion sickness, offering a new option after 40 years.
- Consider the potential side effects, such as drowsiness, and discuss them with your healthcare provider.
- Explore the direct-to-consumer portal at nereus.us&ref=yanuki.com for potential cost savings.
Discussion
What are your experiences with motion sickness treatments? Do you think NEREUS™ will be a game-changer? Share this article with others who need to stay ahead of this trend!
Sources
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
FDA Approves Tradipitant, First New Motion Sickness Drug in 40 Years
VNDA stock rises after hours on commercial launch of motion sickness drug
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.